Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, Li Z, Kim YJ, Zhou K, Fang Y, Lyu Z, Chen Y, Tian Y, Huang J, Cen X, Husman T, Cho JM, Hsiai T, Zhou JJ, Wang P, Puliafito BR, Larson SM, Yang L.
Li YR, et al. Among authors: fang y.
Mol Ther. 2024 Jun 5;32(6):1849-1874. doi: 10.1016/j.ymthe.2024.04.005. Epub 2024 Apr 6.
Mol Ther. 2024.
PMID: 38584391
Free PMC article.
The (U)CAR-NKT cells are produced with high yield, purity, and robustness, and they display a stable HLA-ablated phenotype that enables resistance to host cell-mediated allorejection. These (U)CAR-NKT cells exhibit potent antitumor efficacy to blood cancers and soli …
The (U)CAR-NKT cells are produced with high yield, purity, and robustness, and they display a stable HLA-ablated phenotype that enabl …